The PurePeptideHub journal
What’s happening in peptide science, and what the evidence actually means. Sourced reporting and thoughtful guides for curious readers.
In the news · Clinical trials
Novo reports new CagriSema results in diabetes and obesity. The comparator, dose, and analysis method are essential to reading the headline.
Read the story12 stories including featured
Clinical trials
Lilly has outlined its EASD presentations. Here is what is scheduled, and which questions to bring to the trial reports.
Regulation
The FDA revised 17 draft product-specific guidances in July. The changes concern generic drug development, not blanket peptide approval.
Research literacy
A reader’s guide to populations, comparators, endpoints, missing data, and the difference between an announcement and a full trial report.
Peptide basics
Understand peptide terminology, why the molecule and formulation matter, and how to tell established medicines from early research.
Lab quality
Country of origin and shipping claims are poor shortcuts for quality. Learn to read import alerts and trace the actual manufacturer and product.
Research literacy
The “Wolverine stack” nickname is not clinical evidence. A guide to combination claims, study limitations, and regulatory context.
Regulation
Understand the difference between approval, compounding, draft guidance, and advisory committee discussion when reading peptide regulation news.
Clinical trials
Retatrutide has reached phase 3 research. Learn how to interpret sponsor results while keeping investigational status and online sales claims separate.
Lab quality
Identity, assay, purity, sterility: learn what a lab report can establish, what it leaves unanswered, and why one number is never the whole story.
Metabolic health
Semaglutide and tirzepatide act on related pathways, but comparing their evidence requires more than a weight-loss headline.
Research literacy
A practical guide to checking interviews, distinguishing discussion from personal use, and avoiding invented celebrity “protocols.”
